‌

US Patent 10669277 Inhibitors of activin receptor-like kinase

Patent 10669277 was granted and assigned to Blueprint Medicines on June, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Blueprint Medicines

Current Assignee

Blueprint Medicines

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

106692770

Date of Patent

June 2, 2020

Patent Application Number

162933170

Date Filed

March 5, 2019

Patent Citations

‌

US Patent 10035789 Compounds useful for treating disorders related to RET

‌

US Patent 10000490 Inhibitors of the fibroblast growth factor receptor

‌

US Patent 10000496 Compositions useful for treating disorders related to kit and PDGFR

‌

US Patent 10017512 Compounds and compositions useful for treating disorders related to NTRK

‌

US Patent 10030005 Inhibitors of RET

‌

US Patent 10233186 Inhibitors of activin receptor-like kinase

Patent Citations Received

‌

US Patent 12071438 Crystal forms of an ALK2 inhibitor

‌

US Patent 11634422 Inhibitors of activin receptor-like kinase

Patent Primary Examiner

‌

Alexander R Pagano

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10669277 Inhibitors of activin receptor-like kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API